Unknown

Dataset Information

0

Restoring Dystrophin Expression in Duchenne Muscular Dystrophy: Current Status of Therapeutic Approaches.


ABSTRACT: Duchenne muscular dystrophy (DMD), a rare genetic disorder characterized by progressive muscle weakness, is caused by the absence or a decreased amount of the muscle cytoskeletal protein dystrophin. Currently, several therapeutic approaches to cure DMD are being investigated, which can be categorized into two groups: therapies that aim to restore dystrophin expression, and those that aim to compensate for the lack of dystrophin. Therapies that restore dystrophin expression include read-through therapy, exon skipping, vector-mediated gene therapy, and cell therapy. Of these approaches, the most advanced are the read-through and exon skipping therapies. In 2014, ataluren, a drug that can promote ribosomal read-through of mRNA containing a premature stop codon, was conditionally approved in Europe. In 2016, eteplirsen, a morpholino-based chemical capable of skipping exon 51 in premature mRNA, received conditional approval in the USA. Clinical trials on vector-mediated gene therapy carrying micro- and mini- dystrophin are underway. More innovative therapeutic approaches include CRISPR/Cas9-based genome editing and stem cell-based cell therapies. Here we review the current status of therapeutic approaches for DMD, focusing on therapeutic approaches that can restore dystrophin.

SUBMITTER: Shimizu-Motohashi Y 

PROVIDER: S-EPMC6462907 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC11197810 | biostudies-literature
| S-EPMC8995704 | biostudies-literature
| S-EPMC7922390 | biostudies-literature
| S-EPMC10789850 | biostudies-literature
| S-EPMC3124804 | biostudies-literature
| S-EPMC3049433 | biostudies-literature
| S-EPMC7480922 | biostudies-literature
| S-EPMC4480531 | biostudies-literature
| S-EPMC6171037 | biostudies-literature
| S-EPMC1299132 | biostudies-literature